图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.v13.i3.10
pages 189-227

Biological Characteristics of Cancers Involving the Serosal Cavities

Ben Davidson
Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Montebello N-0310 Oslo; Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, Oslo, Norway

ABSTRACT

The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival. Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site. Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure. In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases. Our data show that a large number of cancer-associated molecules, including cell adhesion proteins, proteolytic enzymes, growth factor receptors, signaling molecules, and transcription factors, are differentially expressed along tumor progression and have a different prognostic value, depending on the organ sampled. In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression. The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.


Articles with similar content:

RUNX1 Mutations in Clonal Myeloid Disorders: From Conventional Cytogenetics to Next Generation Sequencing, A Story 40 Years in the Making
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
James K. Mangan , Nancy A. Speck
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Jun Du, Xiao-Jun Zhou
Signaling Networks that Control the Lineage Commitment and Differentiation of Bone Cells
Critical Reviews™ in Eukaryotic Gene Expression, Vol.19, 2009, issue 1
Shuying Yang, Wei Chen, Carrie S. Soltanoff, Yi-Ping Li
Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target
Critical Reviews™ in Immunology, Vol.35, 2015, issue 5
Simone Burgler